These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 39061093)

  • 1. Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
    Freet CS; Evans B; Brick TR; Deneke E; Wasserman EJ; Ballard SM; Stankoski DM; Kong L; Raja-Khan N; Nyland JE; Arnold AC; Krishnamurthy VB; Fernandez-Mendoza J; Cleveland HH; Scioli AD; Molchanow A; Messner AE; Ayaz H; Grigson PS; Bunce SC
    Addict Sci Clin Pract; 2024 Jul; 19(1):56. PubMed ID: 39061093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats.
    Evans B; Stoltzfus B; Acharya N; Nyland JE; Arnold AC; Freet CS; Bunce SC; Grigson PS
    Brain Res Bull; 2022 Oct; 189():163-173. PubMed ID: 36038016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats.
    Urbanik LA; Acharya NK; Grigson PS
    Brain Res Bull; 2022 Oct; 189():155-162. PubMed ID: 36031011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
    JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial.
    Garland EL; Hanley AW; Kline A; Cooperman NA
    Drug Alcohol Depend; 2019 Oct; 203():61-65. PubMed ID: 31404850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using ecological momentary assessments of negative affect and craving during residential opioid use disorder treatment to predict patients' relapse to substance use.
    Cleveland HH; Knapp KS; Cleveland MJ; Deneke E; Bunce SC
    J Subst Use Addict Treat; 2023 Mar; 146():208931. PubMed ID: 36880896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment.
    Kowalczyk WJ; Moran LM; Bertz JW; Phillips KA; Ghitza UE; Vahabzadeh M; Lin JL; Epstein DH; Preston KL
    Am J Drug Alcohol Abuse; 2018; 44(5):502-511. PubMed ID: 29634425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prefrontal cortical response to natural rewards and self-reported anhedonia are associated with greater craving among recently withdrawn patients in residential treatment for opioid use disorder.
    Petrie DJ; Knapp KS; Freet CS; Deneke E; Brick TR; Cleveland HH; Bunce SC
    Brain Res Bull; 2022 Nov; 190():32-41. PubMed ID: 36122801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture-model approach to classifying patients.
    Burgess-Hull AJ; Smith KE; Schriefer D; Panlilio LV; Epstein DH; Preston KL
    Drug Alcohol Depend; 2021 Sep; 226():108884. PubMed ID: 34229153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
    Klein MR; Darnall BD; You DS
    JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
    Sandsdal RM; Juhl CR; Jensen SBK; Lundgren JR; Janus C; Blond MB; Rosenkilde M; Bogh AF; Gliemann L; Jensen JB; Antoniades C; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    Cardiovasc Diabetol; 2023 Feb; 22(1):41. PubMed ID: 36841762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
    Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients.
    Huhn AS; Sweeney MM; Brooner RK; Kidorf MS; Tompkins DA; Ayaz H; Dunn KE
    Neuropsychopharmacology; 2019 Mar; 44(4):826-833. PubMed ID: 30375498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial.
    van Ruiten CC; Ten Kulve JS; van Bloemendaal L; Nieuwdorp M; Veltman DJ; IJzerman RG
    Psychoneuroendocrinology; 2022 Mar; 137():105667. PubMed ID: 35033928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.